Capital Group Identifies Attractive Dividend Stock Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy HIMS?
Source: CNBC
- Dividend Stock Appeal: Christopher Buchbinder from Capital Group highlights the attractiveness of dividend stocks, particularly those rated investment grade with a long history of income payments, which has allowed the CGDV fund to outperform the S&P 500 in down markets.
- Tech Sector Allocation: As of January 31, 26.8% of CGDV's assets are allocated to information technology, particularly semiconductor companies, reflecting the team's confidence in a sustainable AI investment cycle, with expectations that AI will dramatically change lives over the next 5-10 years.
- Energy Sector Opportunities: Although energy comprises only 6.4% of CGDV's portfolio, Buchbinder sees an upcycle in the oil field services sector over the next few years, particularly with Halliburton's collaboration with VoltaGrid to manufacture power systems for AI data centers, indicating long-term growth potential.
- Healthcare Investment: CGDV's largest healthcare holding is Eli Lilly at 3.86%, with Buchbinder believing that the long-term trend of GLP-1 drugs will transform the healthcare landscape in the U.S., positioning Eli Lilly as the market leader while awaiting FDA approval for its oral GLP-1 drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Partners with Novo Nordisk for Weight-Loss Drugs
- Stock Surge: Hims & Hers Health closed at $22.15 on Monday, up 40.72%, primarily driven by the announcement of a collaboration with Novo Nordisk to sell GLP-1 weight-loss drugs, indicating strong market optimism for future growth.
- Volume Spike: The trading volume reached 168.1 million shares, about 557% above its three-month average of 25.6 million shares, reflecting heightened investor interest and increased market activity following the new partnership.
- Analyst Upgrades: Analysts at Needham and Citi raised their price targets for Hims & Hers to $30 and $24, respectively, signaling increased confidence in the company's future profitability, even as its stock remains down 62% from its 52-week high.
- Competitive Market Pressure: Despite the strong stock performance, the Motley Fool analyst team did not include Hims & Hers in their current list of top investment stocks, advising investors to carefully consider potential risks while pursuing high returns.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Hims & Hers Receives Upgrade Following Novo Nordisk Agreement, But Stock Gains May Remain Constrained.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
European Natural Gas Prices Hit Three-Year High Amid Geopolitical Tensions
- Price Surge: European natural gas prices soared to a three-year high on Tuesday due to ongoing US-Israeli military operations against Iran, with the Dutch TTF rising 68% for the week ending March 6, indicating potential long-term disruptions to LNG supplies.
- Inventory Decline: The Energy Information Administration reported a draw of 132 bcf in natural gas inventories for the week ending February 27, exceeding market expectations of 124 bcf, highlighting increasing supply tightness that could lead to further price hikes.
- Market Reaction: West Texas Intermediate crude surged nearly 30% to $120 a barrel on Sunday night before dropping 15% to near $100, reflecting the market's heightened sensitivity to Middle Eastern energy supply concerns, which may destabilize global energy markets.
- Economic Outlook: Although the economic impact of the Iran conflict has yet to materialize, weak industrial production data from the Euro Area and the UK indicates fragile growth, with traders anticipating two rate cuts from the European Central Bank this year, reflecting concerns about future economic conditions.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
Hims & Hers Partners with Novo Nordisk for Weight-Loss Drugs
- Stock Surge: Hims & Hers Health closed at $22.15 on Monday, up 40.72%, primarily driven by the announcement of a collaboration with Novo Nordisk to sell GLP-1 weight-loss drugs, indicating strong market optimism for future growth.
- Volume Spike: The trading volume reached 168.1 million shares, about 557% above its three-month average of 25.6 million shares, reflecting heightened investor interest and increased market activity following the new partnership.
- Analyst Upgrades: Analysts at Needham and Citi raised their price targets for Hims & Hers to $30 and $24, respectively, signaling increased confidence in the company's future profitability, even as its stock remains down 62% from its 52-week high.
- Competitive Market Pressure: Despite the strong stock performance, the Motley Fool analyst team did not include Hims & Hers in their current list of top investment stocks, advising investors to carefully consider potential risks while pursuing high returns.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Hims & Hers Receives Upgrade Following Novo Nordisk Agreement, But Stock Gains May Remain Constrained.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
European Natural Gas Prices Hit Three-Year High Amid Geopolitical Tensions
- Price Surge: European natural gas prices soared to a three-year high on Tuesday due to ongoing US-Israeli military operations against Iran, with the Dutch TTF rising 68% for the week ending March 6, indicating potential long-term disruptions to LNG supplies.
- Inventory Decline: The Energy Information Administration reported a draw of 132 bcf in natural gas inventories for the week ending February 27, exceeding market expectations of 124 bcf, highlighting increasing supply tightness that could lead to further price hikes.
- Market Reaction: West Texas Intermediate crude surged nearly 30% to $120 a barrel on Sunday night before dropping 15% to near $100, reflecting the market's heightened sensitivity to Middle Eastern energy supply concerns, which may destabilize global energy markets.
- Economic Outlook: Although the economic impact of the Iran conflict has yet to materialize, weak industrial production data from the Euro Area and the UK indicates fragile growth, with traders anticipating two rate cuts from the European Central Bank this year, reflecting concerns about future economic conditions.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
